MetaVia Inc. announced acceptance of a late-breaking abstract on DA-1726, its obesity treatment candidate, for poster presentation at EASL Congress 2026.
Key takeaways
Late-breaking abstract on DA-1726 accepted for poster presentation at EASL Congress 2026 in Barcelona, Spain, May 27–30.
DA-1726 is a novel dual oxyntomodulin analog targeting GLP-1 and glucagon receptors for obesity and MASH treatment.
Phase 1 Part 3 titration study ongoing with data expected in Q4 2026.
Poster presentation on May 27, 2026, at 8:30 am CET by Chief Medical Officer Chris Fang.
In Phase 1 MAD trial, 32 mg dose showed potential for weight loss, glucose control, and waist reduction.